Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Rifabutin on Cabotegravir PK
NCT03149848Phase 1Completed
- Sponsor
- ViiV Healthcare
- Start
- Jun 2017
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cabotegravir in human immunodeficiency virus infection (HIV), sponsored by ViiV Healthcare. Primary endpoints: Area Under the Concentration-time Curve Over One Dosing Interval (AUC [0 to Tau]) at Day 28 and Maximum Observed Concentration at Day 28. Started Jun 2017; status: completed.
02
Drugs
cabotegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03149848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03149848.